Baker McKenzie has advised Takeda. Skadden has advised Innovent Biologics. Takeda has entered into a global strategic partnership with Innovent Biologics, aimed at strengthening Takeda’s oncology...
Takeda Enters Global Strategic Partnership with Innovent Biologics for Oncology Pipeline Expansion
Incyte’s AI-focused Research Collaboration with Genesis Therapeutics
Baker McKenzie advised Incyte on the deal. Global biopharmaceutical company, Incyte (Nasdaq: INCY), has announced a strategic collaboration agreement with Genesis Therapeutics for the use of...
Lundbeck’s $2.6 Billion Acquisition of Longboard Pharmaceuticals
Baker McKenzie represented H.Lundbeck A/S (Lundbeck) in the transaction, Cooley represented Longboard Pharmaceuticals and Wilson Sonsini Goodrich & Rosati represented Evercore, Longboard’s financial advisor. H. Lundbeck...
CureVac’s Collaboration with MD Anderson
Baker McKenzie advised CureVac N.V. on the deal. CureVac N.V., a global biopharmaceutical company developing transformative medicines based on messenger ribonucleic acid (mRNA), entered into a...
Takeda’s License and Collaboration Agreement for Rusfertide
Baker McKenzie acted as legal counsel to Takeda. Takeda signed a worldwide license and collaboration agreement with Protagonist Therapeutics, Inc., for the development and commercialization of...
Minoryx Therapeutics and Neuraxpharm Group’s Development of a New CNS Therapy in Europe
Baker McKenzie advised Minoryx Therapeutics on the deal. Clifford Chance advised the Neuraxpharm Group. Minoryx Therapeutics, a late-stage biotech company focused on the development of treatments...